Davis Investment Partners LLC Sells 1,724 Shares of Amgen Inc. $AMGN

Davis Investment Partners LLC lowered its stake in Amgen Inc. (NASDAQ:AMGN) by 37.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,876 shares of the medical research company’s stock after selling 1,724 shares during the period. Davis Investment Partners LLC’s holdings in Amgen were worth $1,212,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. State Street Corp boosted its holdings in Amgen by 38.2% during the second quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after acquiring an additional 11,656,755 shares during the period. Bank of America Corp DE acquired a new stake in shares of Amgen in the second quarter valued at about $1,831,903,000. Wellington Management Group LLP grew its position in shares of Amgen by 1,102.7% in the second quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company’s stock valued at $993,031,000 after purchasing an additional 2,514,254 shares during the last quarter. BlackRock Inc. grew its position in shares of Amgen by 4.8% in the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock valued at $17,874,974,000 after purchasing an additional 2,261,544 shares during the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in shares of Amgen by 702.8% in the third quarter. Assenagon Asset Management S.A. now owns 1,535,257 shares of the medical research company’s stock worth $647,126,000 after purchasing an additional 1,344,010 shares during the period. Institutional investors and hedge funds own 76.50% of the company’s stock.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: New data presented at the American Heart Association’s 2026 Scientific Sessions strengthened the case for earlier and more intensive Repatha treatment. Amgen cited an analysis finding the drug highly cost-effective in high-risk patients without a prior heart attack or stroke, and a long-term analysis associating it with a 29% lower risk of major cardiovascular events in patients with existing cardiovascular disease. These findings could support Repatha’s clinical profile and adoption, although the reported evidence includes an external-control analysis. Read article
• Neutral Sentiment: Investors are watching for ACR conference data on dazodalibep. The coverage frames the results as a test for the program, but the provided reports do not disclose findings, so the clinical and stock impact remains uncertain. Read article
• Neutral Sentiment: Recent coverage also compares Amgen’s dividend income and valuation with Regeneron’s faster growth, while another report says analyst views on Amgen are mixed. Neither item provides a specific new forecast or rating change that clearly shifts the near-term outlook. Read article

Amgen Price Performance

Shares of Amgen stock opened at $465.23 on Wednesday. The company has a debt-to-equity ratio of 3.60, a current ratio of 1.48 and a quick ratio of 1.20. Amgen Inc. has a fifty-two week low of $312.39 and a fifty-two week high of $483.99. The firm has a fifty day moving average price of $423.79 and a two-hundred day moving average price of $379.39. The company has a market cap of $251.65 billion, a PE ratio of 26.99, a price-to-earnings-growth ratio of 3.25 and a beta of 0.43.

Amgen (NASDAQ:AMGN) last posted its quarterly earnings results on Tuesday, November 3rd. The medical research company reported $6.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.79 by $0.66. Amgen had a net margin of 24.14% and a return on equity of 114.99%. The company had revenue of $10.37 billion for the quarter, compared to analyst estimates of $10.07 billion. During the same period last year, the business posted $5.64 EPS. The business’s quarterly revenue was up 8.5% on a year-over-year basis. Analysts expect that Amgen Inc. will post 23.33 EPS for the current year.

Amgen Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, December 11th. Investors of record on Friday, November 20th will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.2%. The ex-dividend date is Friday, November 20th. Amgen’s dividend payout ratio (DPR) is presently 58.47%.

Insider Buying and Selling at Amgen

In related news, SVP Rachna Khosla sold 1,252 shares of Amgen stock in a transaction dated Thursday, August 13th. The stock was sold at an average price of $416.43, for a total transaction of $521,370.36. Following the sale, the senior vice president directly owned 6,404 shares of the company’s stock, valued at $2,666,817.72. This trade represents a 16.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.85% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on the company. Argus boosted their price objective on Amgen from $375.00 to $460.00 and gave the stock a “buy” rating in a research report on Wednesday, August 19th. Canaccord Genuity Group increased their target price on Amgen from $384.00 to $440.00 and gave the company a “hold” rating in a research note on Wednesday, November 4th. Oppenheimer reaffirmed an “outperform” rating on shares of Amgen in a report on Friday, October 23rd. TD Cowen lifted their price target on Amgen from $452.00 to $531.00 and gave the stock a “buy” rating in a research report on Wednesday, November 4th. Finally, Guggenheim lifted their price target on Amgen from $378.00 to $435.00 and gave the stock a “neutral” rating in a research report on Thursday, November 5th. One research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, eighteen have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Amgen presently has an average rating of “Hold” and a consensus target price of $422.76.

Amgen Profile

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.